Stanford Cancer Institute
Showing 101-200 of 513 Results
-
Xianjin Dai, PhD, DABR
Assistant Professor of Radiation Oncology (Radiation Physics)
Current Research and Scholarly InterestsIntelligent Image-guided intervention
AI in Medicine
Medical Image Analysis
Biomedical Physics
Multimodal Imaging
Ultrasound Imaging
Medical Device
Biomedical Optics (Optical, Photoacoustic, OCT) -
Heike Daldrup-Link
Professor of Radiology (General Radiology) and, by courtesy, of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsAs a physician-scientist involved in the care of pediatric patients and developing novel pediatric molecular imaging technologies, my goal is to link the fields of nanotechnology and medical imaging towards more efficient diagnoses and image-guided therapies. Our research team develops novel imaging techniques for improved cancer diagnosis, for image-guided-drug delivery and for in vivo monitoring of cell therapies in children and young adults.
-
Edward J. Damrose, MD, FACS
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Anesthesiology, Perioperative & Pain Medicine (MSD)
Current Research and Scholarly InterestsAdvanced MRI imaging for laryngeal cancer and swallowing disorders; applications of robotics in microlaryngeal surgery; high speed digital imaging of vocal fold vibration; the effects of hormones and anabolic steroids on vocal function.
-
Bruce Daniel
Professor of Radiology (Body Imaging) and, by courtesy, of Bioengineering
Current Research and Scholarly Interests1. MRI of Breast Cancer, particularly new techniques. Currently being explored are techniques including ultra high spatial resolution MRI and contrast-agent-free detection of breast tumors.
2. MRI-guided interventions, especially MRI-compatible remote manipulation and haptics
3. Medical Mixed Reality. Currently being explored are methods of fusing patients and their images to potentially improve breast conserving surgery, and other conditions. -
Kyle Gabriel Daniels
Assistant Professor of Genetics and, by courtesy, of Neurosurgery (Adult Neurosurgery)
BioKyle obtained his BS in Biochemistry from the University of Maryland College Park in 2010, conducting undergraduate research with Dr. Dorothy Beckett, PhD. He obtained his PhD in Biochemistry with a certificate in Structural Biology and Biophysics. His dissertation is titled "Kinetics of Coupled Binding and Conformational Change in Proteins and RNA" and was completed in the laboratory of Dr. Terrence G. Oas, PhD. Kyle performed postdoctoral training with Dr. Wendell A. Lim, PhD at UCSF studying how CAR T cell phenotype is encoded by modular signaling motifs within chimeric antigen receptors.
Kyle's lab is interested in harnessing the principles of modularity to engineer receptors and gene circuits to control cell functions.
The lab will use synthetic biology, medium- and high-throughput screens, and machine learning to: (1) Engineer immune cells to achieve robust and durable responses against various cancer targets, (2) Coordinate behavior of multiple engineered cell types in cancer, autoimmune disease, and payload delivery, (3) Control survival, proliferation, and differentiation of hematopoietic stem cells (HSCs) and immune cells, and (4) Explore principles of modularity related to engineering receptors and gene circuits in mammalian cells. -
Millie Das
Clinical Professor, Medicine - Oncology
BioDr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is Chief of Oncology at the Palo Alto VA and is an active member of the VA national Lung Cancer Working Group and Lung Cancer Precision Oncology Program. In 2023, she was elected President the Association of Northern California Oncologists (ANCO), where she displays her passion for patient advocacy and also for clinician education by helping to organize Bay Area focused continuing medical education programs. She is the VA site director for the Stanford fellowship program and leads the VA thoracic tumor board on a biweekly basis. She has a strong interest in clinical research, serving as a principal investigator for multiple clinical and translational studies at the Palo Alto VA, and also as a co-investigator on all of the lung cancer trials at Stanford. In her free time, she enjoys spending time with her family, traveling, and running.
-
Kara Davis
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.
-
Mark M. Davis
Burt and Marion Avery Family Professor
Current Research and Scholarly InterestsMolecular mechanisms of lymphocyte recognition and differentiation; Systems immunology and human immunology; vaccination and infection.
-
Ronald W. Davis
Professor of Biochemistry and of Genetics
Current Research and Scholarly InterestsWe are using Saccharomyces cerevisiae and Human to conduct whole genome analysis projects. The yeast genome sequence has approximately 6,000 genes. We have made a set of haploid and diploid strains (21,000) containing a complete deletion of each gene. In order to facilitate whole genome analysis each deletion is molecularly tagged with a unique 20-mer DNA sequence. This sequence acts as a molecular bar code and makes it easy to identify the presence of each deletion.
-
Aaron J. Dawes, MD, PhD, FACS, FASCRS
Assistant Professor of Surgery (General Surgery)
BioDr. Dawes is a board-certified, fellowship-trained colon and rectal surgeon. He is also an Assistant Professor in the Department of Surgery, Division of General Surgery at Stanford University School of Medicine.
Dr. Dawes treats a wide variety of conditions involving the colon, rectum, and anus, always leveraging the latest evidence and technologies. He is fully trained in minimally invasive surgical techniques--including laparoscopic, robotic, and trans-anal minimally invasive surgery--and strives to employ them, whenever possible, in an effort to reduce pain and shorten recovery.
In addition to his clinical work, Dr. Dawes is a health services researcher, receiving his Ph.D. in Health Policy and Management from the UCLA Fielding School of Public Health. His research focuses on policy development, measurement, and evaluation for patients with colorectal conditions. He is particularly interested in using data to drive policy interventions aimed at reducing disparities in quality, access, and value.
Prior to joining Stanford, Dr. Dawes completed a residency in General Surgery at the University of California, Los Angeles followed by a fellowship in Colon and Rectal Surgery at the University of Minnesota. He has authored articles in the Journal of the American Medical Association (JAMA), Cancer, Diseases of the Colon and Rectum, Health Services Research, and JAMA Surgery. His work has also been featured in the Los Angeles Times, the Daily Press, and HealthDay News.
A native of the San Francisco Bay Area, Dr. Dawes received his A.B. in Public and International Affairs from Princeton University and his M.D. from Vanderbilt University. -
Adam de la Zerda
Associate Professor of Structural Biology and, by courtesy, of Electrical Engineering
Current Research and Scholarly InterestsMolecular imaging technologies for studying cancer biology in vivo
-
Daniel James Delitto, MD, PhD, FACS
Assistant Professor of Surgery (General Surgery)
BioDr. Delitto is a board certified complex general surgical oncologist with a focus on conditions of the liver, pancreas, and stomach. He is an assistant professor in Stanford Medicine’s Department of Surgery.
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists. -
Wendy DeMartini
Professor of Radiology (Breast Imaging)
On Leave from 09/08/2025 To 05/31/2026BioDr. Wendy DeMartini is a Professor in the Department of Radiology at Stanford University School of Medicine. She currently serves as the Associate Chair for Clinical Faculty Affairs in the Department of Radiology, and is the past Division Chief of Breast Imaging. Her work is focused upon high quality patient care, clinical research and education.
Dr. DeMartini completed her fellowship in Breast Imaging at the University of Washington School of Medicine in Seattle, Washington. She then served as Breast Imaging faculty at the University of Washington where she became Associate Professor and Associate Director of Clinical Services, and at the University of Wisconsin where she became Professor and Chief of Breast Imaging.
Dr. DeMartini has more than 100 research presentations, abstracts/publications, review articles or book chapters. Her research is directed toward the appropriate evidence-based use of imaging tests to optimize the detection and evaluation of breast cancer. She has served as an investigator on several studies of breast MRI funded by the National Cancer Institute and by the American College of Radiology Imaging Network (ACRIN). Particular research topics have included the development of a pilot tool for predicting the probability of malignancy of breast MRI lesions, assessment of the impact of background parenchymal enhancement (BPE) on breast MRI accuracy, and evaluation of utilization patterns of breast MRI and other emerging technologies. She also served as the Editor-in-Chief of the Journal of Breast Imaging from 2023 to 2024.
Dr. DeMartini is a highly sought-after educator. She lectures on a broad spectrum of breast imaging topics nationally and internationally, including in the Americas, Europe, Australasia and Africa. She is the past Co-Director of the American College of Radiology (ACR) Education Center Breast MRI with Biopsy Course. Dr. DeMartini is an active member of many professional organizations and committees, including in the Radiologic Society of North America, the American College of Radiology and the Society of Breast Imaging (SBI). She was elected as an SBI Fellow in 2009 and served as President of the SBI in 2017-2018. -
Utkan Demirci
Professor of Radiology (Diagnostic Sciences Laboratory) and, by courtesy, of Electrical Engineering
BioDr. Utkan Demirci, UofM’99, Stanford’01’05’05, is a Professor of Radiology (with tenure) and of Electrical Engineering (by courtesy) at the Canary Center at Stanford for Cancer Early Detection, Stanford University School of Medicine, where he leads a productive researcher group. Utkan is a tenured professor at Stanford University School of Medicine. Prior to joining Stanford in 2014, he held the position of Associate Professor at the Brigham and Women’s Hospital-Harvard Medical School and also served at the Harvard-MIT Health Sciences and Technology division. Over the past decade, his research group has focused on the early detection of cancer and has made significant contributions to the development of microfluidic platforms for sorting rare cells and exosomes and point-of-care bio-sensing technologies.
Dr. Demirci leads a productive and impactful research group focused on addressing problems from the clinic with innovations including cell sorter for IVF, optical technologies for detecting viruses, portable point of care technologies for diagnostics in global health, smart robots in vivo, extracellular vesicle based early detection approaches for cancer. He is an elected fellow of the American Institute of Medical and Biological Engineering and The Academy for Radiology & Biomedical Imaging Research Distinguished Investigator.
He has published over 250 peer-reviewed articles, 300 abstracts and proceedings, 24 book chapters and editorials, and 7 edited books. He also serves on the editorial board of various journals. He is a serial academic entrepreneur and co-founded multiple successful companies. His patents are translated into broadly used biomedical products. Dr. Demirci's pioneering work in microfluidics and cell sorting has resulted in CE certified and FDA approved devices used in over 500,000 clinical cases serving patients globally. -
Atman Desai, MD
Clinical Professor, Neurosurgery
Current Research and Scholarly InterestsThe Stanford Spine Artificial Intelligence Laboratory develops data-driven technologies to improve diagnosis, surgical planning, and outcomes in spine care. Our research spans predictive modeling, computational imaging, spinal oncology, digital surgery, and real-world functional assessment using wearables. By integrating clinical, imaging, and functional data at scale, we aim to deliver clinically meaningful, patient-centered innovations for complex spinal disease.
-
Kaniksha Desai
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism
BioDr. Kaniksha Desai is a board-certified endocrinologist and clinical associate professor at Stanford University. She completed her endocrinology fellowship at the Mayo Clinic, with an emphasis on the management of patients with thyroid cancer. Dr. Desai’s clinical practice focuses on the management of patients with thyroid nodules and thyroid cancer. She also maintains board certification in neck ultrasonography.
-
Manisha Desai (She/Her/Hers)
Kim and Ping Li Professor, Professor (Research) of Medicine (Quantitative Sciences Unit), of Biomedical Data Science and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Desai is the Director of the Quantitative Sciences Unit. She is interested in the application of biostatistical methods to all areas of medicine including oncology, nephrology, and endocrinology. She works on methods for the analysis of epidemiologic studies, clinical trials, and studies with missing observations.
-
Tushar Desai
Professor of Medicine (Pulmonary, Allergy and Critical Care Medicine)
Current Research and Scholarly InterestsBasic and translational research in lung stem cell biology, cancer, pulmonary fibrosis, COPD, and acute lung injury/ARDS. Upper airway stem cell CRISPR gene correction followed by autologous stem cell transplantation to treat Cystic fibrosis. Using lung organoids and precision cut lung slice cultures of mouse and human lungs to study molecular regulation of lung stem cells. Using transgenic mice to visualize Wnt protein transmission from niche cell to stem cell in vivo.
-
Joseph M. DeSimone
Sanjiv Sam Gambhir Professor of Translational Medicine, Professor of Chemical Engineering and, by courtesy, of Chemistry, of Materials Science and Engineering, and of Operations, Information and Technology at the Graduate School of Business
BioJoseph M. DeSimone is the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University. He holds appointments in the Departments of Radiology and Chemical Engineering with courtesy appointments in the Department of Chemistry and in Stanford’s Graduate School of Business.
The DeSimone laboratory's research efforts are focused on developing innovative, interdisciplinary solutions to complex problems centered around advanced polymer 3D fabrication methods. In Chemical Engineering and Materials Science, the lab is pursuing new capabilities in digital 3D printing, as well as the synthesis of new polymers for use in advanced additive technologies. In Translational Medicine, research is focused on exploiting 3D digital fabrication tools to engineer new vaccine platforms, enhanced drug delivery approaches, and improved medical devices for numerous conditions, with a current major focus in pediatrics. Complementing these research areas, the DeSimone group has a third focus in Entrepreneurship, Digital Transformation, and Manufacturing.
Before joining Stanford in 2020, DeSimone was a professor of chemistry at the University of North Carolina at Chapel Hill and of chemical engineering at North Carolina State University. He is also Co-founder, Board Chair, and former CEO (2014 - 2019) of the additive manufacturing company, Carbon. DeSimone is responsible for numerous breakthroughs in his career in areas including green chemistry, medical devices, nanomedicine, and 3D printing. He has published over 350 scientific articles and is a named inventor on over 200 issued patents. Additionally, he has mentored 80 students through Ph.D. completion in his career, half of whom are women and members of underrepresented groups in STEM.
In 2016 DeSimone was recognized by President Barack Obama with the National Medal of Technology and Innovation, the highest U.S. honor for achievement and leadership in advancing technological progress. He has received numerous other major awards in his career, including the U.S. Presidential Green Chemistry Challenge Award (1997); the American Chemical Society Award for Creative Invention (2005); the Lemelson-MIT Prize (2008); the NIH Director’s Pioneer Award (2009); the AAAS Mentor Award (2010); the Heinz Award for Technology, the Economy and Employment (2017); the Wilhelm Exner Medal (2019); the EY Entrepreneur of the Year Award (2019 U.S. Overall National Winner); and the Harvey Prize in Science and Technology (2020). He is one of only 25 individuals elected to all three branches of the U.S. National Academies (Sciences, Medicine, Engineering). DeSimone received his B.S. in Chemistry in 1986 from Ursinus College and his Ph.D. in Chemistry in 1990 from Virginia Tech. -
Terry Desser
Professor of Radiology (Abdominal Imaging), Emerita
Current Research and Scholarly InterestsImaging of gastrointestinal tract cancer
Ultrasound
Simulated learning environment -
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory focuses on two main areas: 1) cancer stem cell biology and 2) novel biomarkers for identifying the presence of malignant cells (diagnostic), predicting outcome (prognostic), and predicting response to therapy (predictive). Areas of study include cancers of the lung, breast, and gastrointestinal system. Clinically I specialize in the treatment of lung cancer and applications of stereotactic ablative radiotherapy and perform both prospective and retrospective clinical studies.
-
Frederick M. Dirbas, MD
Associate Professor of Surgery (General Surgery) and, by courtesy, of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsCurrently collaborating with Dr's Aaron Newman and Michael Clarke to study cancer stem cells associated with triple negative breast cancer. Advancing studies of FLASH radiotherapy in preclinical models for potential future use in humans. Investigating preclinical use of high dose gaseous nitric oxide in the treatment of solid tumors.
-
Vasu Divi, MD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
BioDr. Vasu Divi is a distinguished expert in the field of head and neck cancer treatment, renowned for his dual roles as a cancer surgeon and reconstructive surgeon. With a specialized focus on high-risk and advanced skin cancers, oral cavity cancers, and osteoradionecrosis of the head and neck, Dr. Divi stands at the forefront of medical innovation. As a national authority in cutaneous squamous cell carcinoma of the head and neck, Dr. Divi spearheads Stanford's clinical trial program dedicated to this condition. His trial portfolio encompasses both neoadjuvant and adjuvant applications of immunotherapy, reflecting his commitment to advancing treatment methodologies. Actively engaged in research, Dr. Divi endeavors to define the optimal treatment approach for this disease, integrating immunotherapy to enhance patient outcomes.
-
Scott Dixon
Professor of Biology
Current Research and Scholarly InterestsMy lab is interested in the relationship between cell death and metabolism. Using techniques drawn from many disciplines my laboratory is investigating how perturbation of intracellular metabolic networks can result in novel forms of cell death, such as ferroptosis. We are interested in applying this knowledge to find new ways to treat diseases characterized by insufficient (e.g. cancer) or excessive (e.g. neurodegeneration) cell death.
-
Sarah S. Donaldson, MD
Catharine and Howard Avery Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsCombined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases -
Fei Dong
Associate Professor of Pathology
BioDr. Dong is the Director of Molecular Pathology at Stanford Health Care. The Molecular Pathology laboratory offers a broad menu of clinical diagnostic tests ranging from PCR to next generation sequencing. Dr. Dong's academic interests include the clinical implementation of laboratory developed tests, the development of novel informatics algorithms, and characterization of disease by molecular methods. Before arriving at Stanford, Dr. Dong was on faculty at Brigham and Women’s Hospital/Harvard Medical School for nine years, where he established a track record in education and mentorship and was the recipient of both the Anatomic Pathology and Clinical Pathology resident teaching awards. Dr. Dong has served on committees for the Association for Molecular Pathology, the Clinical and Laboratory Standards Institute, and the United States and Canadian Academy of Pathology. He serves on the editorial boards of multiple scientific journals and is an Associate Editor for the Journal of Molecular Diagnostics.
-
Asiri Ediriwickrema MD, PhD
Assistant Professor of Medicine (Hematology)
BioAsiri Ediriwickrema, MD, PhD, is a physician-scientist who leads a systems hematology laboratory at Stanford and directs a clinical practice focused on myelodysplastic neoplasms and clonal hematopoiesis. Our research group studies hematopoiesis—the complex process by which hematopoietic stem cells generate the diverse blood cells essential for health throughout life. Our mission is to understand how individual blood cells change during aging and cancer development, with particular focus on how dysregulation of this process leads to cytopenias and hematologic malignancies.
We integrate expertise spanning clinical medicine, functional hematology, molecular and cellular biology, genomics, bioinformatics, and machine learning. By combining advanced experimental techniques with computational approaches, we examine blood cell development and function at single-cell resolution. Our work aims to identify the earliest cellular changes in cancer development, map how stem cells interact within their tissue environments, and develop AI-powered tools that predict stem cell behavior and disease progression. Our goal is to translate these efforts into improved diagnostics and precision therapeutic strategies for patients with blood disorders and malignancies.
Dr. Ediriwickrema earned his undergraduate degree in Engineering from the Massachusetts Institute of Technology, his MD (Cum Laude) from Yale University, and his PhD from Stanford University. He completed his residency in Internal Medicine and fellowship in Hematology at Stanford, where he also conducted his doctoral and postdoctoral research in the laboratory of Dr. Ravi Majeti. His research identified novel populations of multipotent progenitor cells in normal hematopoiesis and leukemia stem cells in acute myeloid leukemia (AML). -
Bradley Efron
Max H. Stein Professor and Professor of Statistics and of Biomedical Data Science, Emeritus
Current Research and Scholarly InterestsResearch Interests:
BOOTSTRAP
BIOSTATISTICS
BAYESIAN STATISTICS -
Irmina A. Elliott, MD
Clinical Assistant Professor, Cardiothoracic Surgery
BioDr. Elliott is a thoracic surgeon and clinical assistant professor in the Department of Cardiothoracic Surgery at Stanford University School of Medicine. She provides the complete spectrum of surgical care for lung cancer, esophageal cancer, mediastinal tumors, and more through the Stanford Health Care Thoracic Cancer Program. She specializes in minimally invasive, including robotic, approaches to thoracic surgery.
Dr. Elliott received fellowship training from Stanford University. She completed her residency at UCLA Medical Center.
Her research has received support from the National Institutes of Health. She has investigated cancer cell response to replication stress, outcomes in patients undergoing hyperthermic intrathoracic chemotherapy (HITHOC) for mesothelioma, complications after esophageal surgery, lymph node involvement in patients with carcinoid tumors of the lung, advanced techniques in robotic surgery, and other topics.
She has authored articles that have appeared in the Proceedings of the National Academy of Sciences (PNAS), Annals of Thoracic Surgery, JAMA Surgery, and other peer-reviewed publications. She also has contributed to textbooks including the content on social disparities in lung cancer for the book Social Disparities in Thoracic Surgery.
Dr. Elliott has made presentations to her peers at meetings of the American Association for Thoracic Surgery, Society of Surgical Oncology, Western Thoracic Surgical Association, and other organizations. Presentations focused on surgical treatment of patients with carcinoid tumor of the lung, improvement of mesothelioma patient survival, complications of esophageal surgery, novel targets for cancer treatment, and more. -
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
On Leave from 07/01/2025 To 06/30/2026Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
C. Garrison Fathman
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.
-
David Feldman
Professor of Medicine (Endocrinology, Gerontology and Metabolism), Emeritus
Current Research and Scholarly InterestsStudies of the role of the vitamin D receptor in the action of 1,25-dihydroxyvitamin D, the active vitamin D hormone. Current efforts are evaluating the vitamin D receptor in breast and prostate cancer, osteoporosis and rickets.
-
Marcus Feldman
Burnet C. and Mildred Finley Wohlford Professor
Current Research and Scholarly InterestsHuman genetic and cultural evolution, mathematical biology, demography of China
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
Russell D. Fernald
Benjamin Scott Crocker Professor of Human Biology, Emeritus
Current Research and Scholarly InterestsIn the course of evolution,two of the strongest selective forces in nature,light and sex, have left their mark on living organisms. I am interested in how the development and function of the nervous system reflects these events. We use the reproductive system to understand how social behavior influences the main system of reproductive action controlled by a collection of cells in the brain containing gonodotropin releasing hormone(GnRH)
-
Katherine Ferrara
Professor of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsMy focus is image-guided drug and gene delivery and I am engaged in the design of imaging devices, molecularly-targeted imaging probes and engineered delivery vehicles, drawing upon my education in biology and imaging physics and more than 20 years of experience with the synthesis and labeling of therapeutic particles. My laboratory has unique resources for and substantial experience in synthetic chemistry and ultrasound, CT, MR and PET imaging.
-
James Ferrell
Professor of Chemical and Systems Biology and of Biochemistry
Current Research and Scholarly InterestsMy lab has two main goals: to understand the regulation of mitosis and to understand the systems-level logic of simple signaling circuits. We often make use of Xenopus laevis oocytes, eggs, and cell-free extracts for both sorts of study. We also carry out single-cell fluorescence imaging studies on mammalian cell lines. Our experimental work is complemented by computational and theoretical studies aimed at understanding the design principles and recurring themes of regulatory circuits.
-
Andrey Finegersh, MD, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
BioDr. Finegersh is a fellowship-trained head and neck surgical oncologist with board certification in otolaryngology and an Assistant Professor with the Stanford School of Medicine Department of Otolaryngology.
He specializes in treatment of benign and malignant tumors of the head and neck and has received additional training in microvascular reconstruction and transoral robotic surgery. He takes tremendous pride in providing compassionate care for patients and managing challenging diagnoses.
Dr. Finegersh completed his MD and PhD degrees at the University of Pittsburgh School of Medicine's combined Medical Scientist Training Program. He went on to complete residency in otolaryngology at the University of California San Diego (UCSD) and his fellowship at Stanford University, where he stayed on as faculty.
He has extensive research experience in head and neck cancer epigenetics and completed post-doctoral research at the University of Pittsburgh and UCSD. He has received grants from the NIH and American Academy of Otolaryngology and has an active research lab studying molecular mechanisms of cancer. Dr. Finegersh has additional clinical interests in studying the role of minimally invasive surgery to improve outcomes for head and neck cancer patients. -
Andrew Fire
George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics
Current Research and Scholarly InterestsWhile chromosomal inheritance provides cells with one means for keeping and transmitting genetic information, numerous other mechanisms have (and remain to be) discovered. We study novel cellular mechanisms that enforce genetic constancy and permit genetic change. Underlying our studies are questions of the diversity of inheritance mechanisms, how cells distinguish such mechanisms as "wanted" versus "unwanted", and of the consequences and applications of such mechanisms in health and disease.
-
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine, Emeritus
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.
-
Hunter Fraser
Professor of Biology
Current Research and Scholarly InterestsWe study the evolution of complex traits by developing new experimental and computational methods.
Our work brings together quantitative genetics, genomics, epigenetics, and evolutionary biology to achieve a deeper understanding of how genetic variation shapes the phenotypic diversity of life. Our main focus is on the evolution of gene expression, which is the primary fuel for natural selection. Our long-term goal is to be able to introduce complex traits into new species via genome editing. -
Richard Frock
Assistant Professor of Radiation Oncology (Radiation and Cancer Biology)
On Partial Leave from 04/01/2026 To 12/10/2026Current Research and Scholarly InterestsWe are a functional genomics laboratory interested in elucidating mechanisms of DNA repair pathway choice and genome instability. We use genome-wide repair fate maps of targeted DNA double strand breaks (DSBs) to develop pathway-specific models and combinatorial therapies. Our expertise overlaps many different fields including: genome editing, ionizing radiation, cancer therapeutics, V(D)J and IgH class switch recombination, repair during transcription and replication, and meiosis.
-
Judith Frydman
Donald Kennedy Chair in the School of Humanities and Sciences and Professor of Genetics
Current Research and Scholarly InterestsThe long term goal of our research is to understand how proteins fold in living cells. My lab uses a multidisciplinary approach to address fundamental questions about molecular chaperones, protein folding and degradation. In addition to basic mechanistic principles, we aim to define how impairment of cellular folding and quality control are linked to disease, including cancer and neurodegenerative diseases and examine whether reengineering chaperone networks can provide therapeutic strategies.
-
Margaret T. Fuller
Reed-Hodgson Professor of Human Biology, Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor of Genetics and of Obstetrics/Gynecology (Reproductive and Stem Cell Biology)
Current Research and Scholarly InterestsRegulation of self-renewal, proliferation and differentiation in adult stem cell lineages. Developmental tumor suppressor mechanisms and regulation of the switch from proliferation to differentiation. Cell type specific transcription machinery and regulation of cell differentiation. Developmental regulation of cell cycle progression during male meiosis.
-
Stephen J. Galli, MD
Mary Hewitt Loveless, MD, Professor in the School of Medicine and Professor of Pathology and of Microbiology and Immunology
Current Research and Scholarly InterestsThe goals of Dr. Galli's laboratory are to understand the regulation of mast cell and basophil development and function, and to develop and use genetic approaches to elucidate the roles of these cells in health and disease. We study both the roles of mast cells, basophils, and IgE in normal physiology and host defense, e.g., in responses to parasites and in enhancing resistance to venoms, and also their roles in pathology, e.g., anaphylaxis, food allergy, and asthma, both in mice and humans.
-
Kristen N Ganjoo
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsGiant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Xiaojing Gao
Assistant Professor of Chemical Engineering
Current Research and Scholarly InterestsHow do we design biological systems as “smart medicine” that sense patients’ states, process the information, and respond accordingly? To realize this vision, we will tackle fundamental challenges across different levels of complexity, such as (1) protein components that minimize their crosstalk with human cells and immunogenicity, (2) biomolecular circuits that function robustly in different cells and are easy to deliver, (3) multicellular consortia that communicate through scalable channels, and (4) therapeutic modules that interface with physiological inputs/outputs. Our engineering targets include biomolecules, molecular circuits, viruses, and cells, and our approach combines quantitative experimental analysis with computational simulation. The molecular tools we build will be applied to diverse fields such as neurobiology and cancer therapy.
-
Chris Garcia
Younger Family Professor and Professor of Structural Biology
Current Research and Scholarly InterestsStructural and functional studies of transmembrane receptor interactions with their ligands in systems relevant to human health and disease - primarily in immunity, infection, and neurobiology. We study these problems using protein engineering, structural, biochemical, and combinatorial biology approaches.
-
Christopher Gardner
Rehnborg Farquhar Professor
Current Research and Scholarly InterestsThe role of nutrition in individual and societal health, with particular interests in: plant-based diets, differential response to low-carb vs. low-fat weight loss diets by insulin resistance status, chronic disease prevention, randomized controlled trials, human nutrition, community based studies, Community Based Participatory Research, sustainable food movement (animal rights and welfare, global warming, human labor practices), stealth health, nutrition policy, nutrition guidelines
-
Charles Gawad
Associate Professor of Pediatrics (Hematology/Oncology)
BioOur lab works at the interface of biotechnology, computational biology, cellular biology, and clinical medicine to develop and apply new tools for characterizing genetic variation across single cells within a tissue with unparalleled sensitivity and accuracy. We are focused on applying these technologies to study cancer clonal evolution while patients are undergoing treatment with the aim of identifying cancer clonotypes that are associated with resistance to specific drugs so as to better understand and predict treatment response. We are also applying these methods to understand how more virulent pathogens emerge from a population of bacteria or viruses with an emphasis on developing a deeper understanding of how antibiotic resistance develops.
-
Michael Gensheimer
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
Current Research and Scholarly InterestsIn addition to my clinical research in head and neck and lung cancer, I work on the application of computer science and machine learning to cancer research. I develop tools for analyzing large datasets to improve outcomes and safety of cancer treatment. I developed a machine learning prognostic model using data from around 13,000 patients with metastatic cancer which performs better than traditional models and physicians [PubMed ID 33313792]. We recently completed a prospective randomized study in thousands of patients in which the model was used to help improve advance care planning conversations.
I also work on the methods underpinning observational and predictive modeling research. My open source nnet-survival software that allows use of neural networks for survival modeling has been used by researchers internationally. In collaboration with the Stanford Research Informatics Center, I examined how electronic medical record (EMR) survival outcome data compares to gold-standard data from a cancer registry [PubMed ID 35802836]. The EMR data captured less than 50% of deaths, a finding that affects many studies being published that use EMR outcomes data. -
Andrew Gentles
Associate Professor (Research) of Pathology, of Medicine (BMIR) and, by courtesy, of Biomedical Data Science
Current Research and Scholarly InterestsComputational systems biology
-
Olivier Gevaert
Associate Professor of Medicine (Biomedical Informatics) and of Biomedical Data Science
Current Research and Scholarly InterestsMy lab focuses on biomedical data fusion: the development of machine learning methods for biomedical decision support using multi-scale biomedical data. We primarily use methods based on regularized linear regression to accomplish this. We primarily focus on applications in oncology and neuroscience.
-
Amato J. Giaccia
Jack, Lulu and Sam Willson Professor, Professor of Radiation Oncology, Emeritus
Current Research and Scholarly InterestsDuring the last five years, we have identified several small molecules that kill VHL deficient renal cancer cells through a synthetic lethal screening approach. Another major interest of my laboratory is in identifying hypoxia-induced genes involved in invasion and metastases. We are also investigating how hypoxia regulates gene expression epigenetically.
-
Iris C. Gibbs, MD, FACR, FASTRO
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
Current Research and Scholarly InterestsDr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.
-
Erin Gibson
Assistant Professor of Psychiatry and Behavioral Sciences (Sleep Medicine)
Current Research and Scholarly InterestsGlia make up more than half of the cells in the human brain, but we are just beginning to understand the complex and multifactorial role glia play in health and disease. Glia are decidedly dynamic in form and function. Understanding the mechanisms underlying this dynamic nature of glia is imperative to developing novel therapeutic strategies for diseases of the nervous system that involve aberrant gliogenesis, especially related to changes in myelination.
-
Harcharan Gill
Kathryn Simmons Stamey Professor, Emeritus
Current Research and Scholarly InterestsBenign Prostatic Hyperplasia- Evaluation and development of new minimally invasive techniques
Endourology: developing, designing and evaluating new instruments
Bladder cancer: outcomes of treatment
BPH: cryotherapy and HIFU -
Jeffrey S. Glenn, M.D., Ph.D.
Joseph D. Grant Professor and Professor of Microbiology and Immunology
Current Research and Scholarly InterestsDr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Other interests include exploitation of hepatic stem cells, engineered human liver tissues, liver cancer, and new biodefense antiviral strategies.
-
Gary Glover
Professor of Radiology (Radiological Sciences Lab) and, by courtesy, of Psychology and of Electrical Engineering
Current Research and Scholarly InterestsMy present research is devoted to the advancement of functional magnetic resonance imaging sciences for applications in basic understanding of the brain in health and disease. We collaborate closely with departmental clinicians and with others in the school of medicine, humanities, and the engineering sciences.
-
Jeremy Goldhaber-Fiebert
Professor of Health Policy
BioJeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy and a Core Faculty Member in the Centers for Health Policy and Primary Care and Outcomes Research. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011 and Secretary/Treasurer in 2021.
Past and current research topics:
- Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
-Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
- Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
- Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
- Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity. -
Zinaida Good, Ph.D.
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsOur laboratory integrates cutting-edge synthetic biology, immunology, and machine learning to engineer T cell therapies for cancer and autoimmune diseases. We have 3 research areas:
- Analysis of clinical single-cell and spatial transcriptomics datasets from T cell therapy trials to identify mechanisms of resistance
- Building AI systems to generate T cell designs predicted to improve patient outcomes
- Genetic screens of novel T cell designs in models that mimic key mechanisms of resistance -
Miriam B. Goodman
Mrs. George A. Winzer Professor of Cell Biology
Current Research and Scholarly InterestsWe study the molecular events that give rise to the sensation of touch and chemical stressors that compromise touch sensation in C. elegans. To do this, we use a combination of quantitative behavioral analysis, genetics, in vivo electrophysiology, and heterologous expression of ion channels. We collaborate with physicists and other physiologist to expand our experimental research.
-
Steven Goodman
Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Health Policy
Current Research and Scholarly InterestsI study issues relating to the representation and measurement of evidence in medical research and determinants of the reliability of biomedical research findings. I also do work in evidence synthesis, comparative effectiveness research, and the ethics of clinical research.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of normal and neoplastic hematolymphoid cells with the bone marrow. lymph node and spleen microenvironment and the interactions of these compartments with immune perturbation and dysregulation.
-
Edward Graves
Professor of Radiation Oncology (Radiation Physics), and by courtesy, of Radiology
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, small animal image-guided conformal radiotherapy, immune responses to radiation, immunotherapy and radiotherapy combinations, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023. -
Henry T. (Hank) Greely
Deane F. and Kate Edelman Johnson Professor of Law and, Professor, by courtesy, of Genetics
Current Research and Scholarly InterestsSince 1992 my work has concentrated on ethical, legal, and social issues in the biosciences. I am particularly active on issues arising from neuroscience, human genetics, and stem cell research, with cross-cutting interests in human research protections, human biological enhancement, and the future of human reproduction.
-
Harry B Greenberg
Joseph D. Grant Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsMolecular mechanisms of pathogenesis; determinants of protective immunity; host range and tissue tropism in liver and GI tract pathogenic viruses and studies of vaccines in people.
-
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
William Greenleaf
Professor of Genetics
Current Research and Scholarly InterestsOur lab focuses on developing methods to probe both the structure and function of molecules encoded by the genome, as well as the physical compaction and folding of the genome itself. Our efforts are split between building new tools to leverage the power of high-throughput sequencing technologies and cutting-edge optical microscopies, and bringing these technologies to bear against basic biological questions by linking DNA sequence, structure, and function.
-
Xuejun Gu
Associate Professor of Radiation Oncology (Medical Physics)
Current Research and Scholarly InterestsArtificial intelligence in medicine
Medical imaging and image anlysis
Treatment planning and clinical decision-making
FLASH radiobiology study ; -
James Hallenbeck, MD
Associate Professor of Medicine (Primary Care and Population Health) at the Palo Alto Veterans Affairs Health Care System, Emeritus
Current Research and Scholarly InterestsResearch in hospice and palliative care with emphases on physician education, cultural aspects of end-of-life care, and healthcare system issues.
-
Bonnie Halpern-Felsher
Marron and Mary Elizabeth Kendrick Professor of Pediatrics and Professor, by courtesy, of Epidemiology and Population Health and of Psychiatry and Behavioral Sciences (Child and Adolescent Psychiatry)
Current Research and Scholarly InterestsResearch focuses on developmental, cognitive and psychosocial factors involved in adolescents’ and young adults’ health-related decision-making, perceptions of risk and vulnerability, health communication and risk behavior. My research has focused on understanding and reducing health risk behaviors such as tobacco use, alcohol and marijuana use, risky driving, and risky sexual behavior.
-
Summer Han
Associate Professor (Research) of Neurosurgery, of Medicine (Biomedical Informatics) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy current research focuses on understanding the genetic and environmental etiology of complex disease and developing and evaluating efficient screening strategies based on etiological understanding. The areas of my research interests include statistical genetics, molecular epidemiology, cancer screening, health policy modeling, and risk prediction modeling. I have developed various statistical methods to analyze high-dimensional data to identify genetic and environmental risk factors and their interactions for complex disease.
-
Philip C. Hanawalt
Dr. Morris Herzstein Professor in Biology, Emeritus
Current Research and Scholarly InterestsMy current interest includes two principal areas:
1. The molecular basis for diseases in which the pathway of transcription-coupled DNA repair is defective, including Cockyne syndrome (CS) and UV-sensitive syndrome (UVSS). Patients are severely sensitive to sunlight but get no cancers. See Hanawalt & Spivak, 2008, for review.
2. Transcription arrest by guanine-rich DNA sequences and non-canonical secondary structures. Transcription collisions with replication forks. -
Steven Hancock, MD
Professor of Radiation Oncology (Radiation Therapy), Emeritus
Current Research and Scholarly InterestsOutcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
General adult and pediatric radiation therapy. -
Pehr Harbury
Associate Professor of Biochemistry
Current Research and Scholarly InterestsScientific breakthroughs often come on the heels of technological advances; advances that expose hidden truths of nature, and provide tools for engineering the world around us. Examples include the telescope (heliocentrism), the Michelson interferometer (relativity) and recombinant DNA (molecular evolution). Our lab explores innovative experimental approaches to problems in molecular biochemistry, focusing on technologies with the potential for broad impact.
-
Brian A. Hargreaves
Professor of Radiology (Radiological Sciences Laboratory) and, by courtesy, of Electrical Engineering and of Bioengineering
Current Research and Scholarly InterestsI am interested in magnetic resonance imaging (MRI) applications and augmented reality applications in medicine. These include abdominal, breast and musculoskeletal imaging, which require development of faster, quantitative, and more efficient MRI methods that provide improved diagnostic contrast compared with current methods. My work includes novel excitation schemes, efficient imaging methods and reconstruction tools and augmented reality in medicine.
-
William Haskell
Professor (Research) of Medicine, Emeritus
Current Research and Scholarly InterestsMy major research interests and activities over the next several years will focus on the development and evaluation of the objective measurement of physical activity in free-living populations using a variety of sensing devices and mobile phones for data collection and processing. Also, I will continue to direct the Stanford Heart Network with the major mission being to assist community-based CVD prevention/treatment programs implement more effective heart attack and stroke prevention programs.
-
Trevor Hastie
John A. Overdeck Professor, Professor of Statistics and of Biomedical Data Sciences, Emeritus
Current Research and Scholarly InterestsFlexible statistical modeling for prediction and representation of data arising in biology, medicine, science or industry. Statistical and machine learning tools have gained importance over the years. Part of Hastie's work has been to bridge the gap between traditional statistical methodology and the achievements made in machine learning.
-
Melanie Hayden Gephart
Professor of Neurosurgery and, by courtesy, of Neurology and Neurological Sciences
BioI am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including gliomas, brain metastases, meningiomas, and schwannomas. I direct the Stanford Brain Tumor Center and the Stanford Brain Metastasis Consortium, collaborative unions of physicians and scientists looking to improve our understanding and treatment of brain tumors. My laboratory seeks greater understanding of the mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We study how rare cancer cell populations survive and migrate in the brain, inadvertently supported by native brain cells. We develop novel cerebrospinal fluid-based biomarkers to track brain cancer treatment response, relapse, and neurotoxicity. Our bedside-to-bench-to-bedside research model builds on a foundation of generously donated patient samples, where we test mechanisms of brain cancer growth, develop novel pre-clinical models that reliably recapitulate the human disease, and facilitate clinical trials of new treatments for patients with brain cancer.
www.GephartLab.com
https://stan.md/BrainMets
@HaydenGephartMD -
Gregory M. Heestand, MD
Clinical Associate Professor, Medicine - Oncology
BioDr. Heestand is a board-certified medical oncologist with a focus on gastrointestinal cancers, primarily hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer. He serves as the medical oncology champion of the Stanford Hepatobiliary Tumor Board, as well as the principal investigator of multiple clinical trials. He collaborates with campus laboratories to help develop new biomarker and treatment technologies. He is the former director of the Stanford Oncology Fellowship Program.
Dr. Heestand and his team take great pride in helping patients and their families face gastrointestinal cancer.
Outside of the clinic, Dr. Heestand enjoys playing the piano, teaching his kids about music, cooking for friends and family, and surfing the internet for interesting things to read. -
Sarah Heilshorn
Rickey/Nielsen Professor in the School of Engineering and Professor, by courtesy, of Bioengineering and of Chemical Engineering
Current Research and Scholarly InterestsProtein engineering
Tissue engineering
Regenerative medicine
Biomaterials -
Stefan Heller, PhD, MS
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsOur research focuses on the inner ear, from its earliest manifestation as one of the cranial placodes until it has developed into a mature and functioning organ. We are interested in how the sensory epithelia of the inner ear that harbor the sensory hair cells develop, how the cells mature, and how these epithelia respond to toxic insults. The overarching goal of this research is to find ways to regenerate lost sensory hair cells in mammals.
-
Tina Hernandez-Boussard
Professor of Medicine (Biomedical Informatics), of Biomedical Data Science, of Surgery and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsMy background and expertise is in the field of computational biology, with concentration in health services research. A key focus of my research is to apply novel methods and tools to large clinical datasets for hypothesis generation, comparative effectiveness research, and the evaluation of quality healthcare delivery. My research involves managing and manipulating big data, which range from administrative claims data to electronic health records, and applying novel biostatistical techniques to innovatively assess clinical and policy related research questions at the population level. This research enables us to create formal, statistically rigid, evaluations of healthcare data using unique combinations of large datasets.
